MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC

被引：0
|
作者：
Mamdani, H. [1 ]
Kim, S. [1 ]
Gentzler, R. [2 ]
Furqan, M. [3 ]
Shields, M. D. [4 ]
Jalal, S. I. [4 ]
机构：
[1] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[2] Univ Virginia, Charlottesville, VA USA
[3] Univ Iowa, Iowa City, IA USA
[4] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Small cell lung cancer; Monalizumab; Extensive stage;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13A.03
引用
收藏
页码：S207 / S207
页数：1
相关论文
共 50 条
  • [31] Phase IIIb study of durvalumab plus platinumeetoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab
    Isla, D.
    Arriola, E.
    Garcia Campelo, M. R.
    Marti, C.
    Diz Tain, P.
    Moreno Vega, A. L.
    Piqueras, M. L-B.
    Leon, L.
    Gutierrez Calderon, V.
    Oramas Rodriguez, J. M.
    Majem, M.
    Sanchez-Hernandez, A.
    Aguado de la Rosa, C.
    Alvarez Cabellos, R.
    Marti-Ciriquian, J. L.
    Moreno Paul, A.
    Gonzalez Cordero, M.
    Callejo Mellen, A.
    Baez, L.
    Zugazagoitia, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S98 - S99
  • [32] A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC).
    Komarnitsky, Philip B.
    Lee, Ho-Jin
    Shah, Manan
    Wong, Shekman
    Gauthier, Sanja
    Dziubinski, Juliann
    Osbaugh, Stacy
    Zhang, Fan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC)
    Glisson, Bonnie
    Kazarnowicz, Andrzej
    Nackaerts, Kristiaan
    Orlov, Sergey
    Ramlau, Rodryg
    Besse, Benjamin
    Cobo Dols, Manuel
    Menon, Hari
    Paz-Ares Rodriguez, Luis
    Zhang, Yilong
    Zhu, Min
    Jiang, Yizhou
    Loh, Elwyn
    Gansert, Jennifer
    Dubey, Sarita
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S220 - S221
  • [34] Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)
    Chen, L.
    Zhao, Y.
    Wu, H.
    Hu, X.
    Wu, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
  • [35] Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial☆
    Lee, Siow Ming
    Hewish, Madeleine
    Ahmed, Samreen
    Papadatos-Pastos, Dionysis
    Karapanagiotou, Eleni
    Blackhall, Fiona
    Ford, Amy
    Young, Robin
    Garcia, Angel
    Arora, Arvind
    Hollingdale, Abigail
    Ahmad, Tanya
    Forster, Martin
    Greystoke, Alastair
    Bremner, Fion
    Rudd, Robin
    Farrelly, Laura
    Vaja, Simran
    Hackshaw, Allan
    EUROPEAN JOURNAL OF CANCER, 2025, 215
  • [36] A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy
    Ettinger, D. S.
    Jotte, R. M.
    Gupta, V.
    Allen, A. R.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial
    Jotte, R.
    Conkling, P. R.
    Reynolds, C.
    Shah, C.
    Galsky, M.
    Klein, L.
    Fitzgibbons, J. F.
    McNally, R.
    Oliver, J. W.
    Renschler, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 540 - 541
  • [38] Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy
    Weitzner, Omar
    Yagur, Yael
    Kadan, Yfat
    Beiner, Mario E.
    Fishman, Ami
    Ben Ezry, Emilie
    Komem, Daphna Amitai
    Helpman, Limor
    ONCOLOGIST, 2019, 24 (12): : E1471 - E1475
  • [39] Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC
    Rizvi, N. A.
    Cho, B. Chul
    Reinmuth, N.
    Lee, K. H.
    Ahn, M-J.
    Luft, A.
    van den Heuvel, M.
    Cobo, M.
    Smolin, A.
    Vicente, D.
    Moiseyenko, V.
    Antonia, S. J.
    Le Moulec, S.
    Robinet, G.
    Natale, R.
    Nakagawa, K.
    Zhao, L.
    Stockman, P. K.
    Chand, V.
    Peters, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
    Yoshino, Takayuki
    Hasegawa, Yasuhisa
    Takahashi, Shunji
    Monden, Nobuya
    Homma, Akihiro
    Okami, Kenji
    Onozawa, Yusuke
    Fujii, Masato
    Taguchi, Takahide
    de Blas, Barbara
    Beier, Frank
    Tahara, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 524 - 531
12345